Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30965862 | 0.71 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL21585195 | 0.70 | P2RX7 (0.40) | P2RX7MAPK1 | |
| SCHEMBL25483074 | 0.70 | USP30 (0.38) | P2RX7MAPK1 | |
| SCHEMBL18095998 | 0.68 | P2RX7 (0.48) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL25136361 | 0.68 | MAPK1 (0.46) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL3655929 | 0.67 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30708588 | 0.67 | P2RX7 (0.43) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2753979 | 0.67 | P2RX7 (0.43) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL31570487 | 0.67 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL3652609 | 0.66 | P2RX7 (0.42) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| WO-2021154669-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | P2RX7 17/4885MAPK1 389/4885LPL 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.